<DOC>
	<DOCNO>NCT00333788</DOCNO>
	<brief_summary>The study continue assess safety certolizumab pegol ( CDP870 ) well examine evolution long term efficacy Crohn 's disease patient complete study C87042 [ NCT00308581 ] . It also assess effect subcutaneous CDP870 400 mg direct cost parameter .</brief_summary>
	<brief_title>Follow-up Welcome Study C87042 NCT00308581 Examining Certolizumab Pegol ( CDP870 ) Subjects With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patients complete study C87042 [ NCT00308581 ] ( previously treat infliximab ) Subject withdraw C87042 [ NCT00308581 ] study Subject receive treatment certolizumab pegol medication permit C87042 [ NCT00308581 ] study Subjects country certolizumab pegol authorize Crohn 's disease treatment Female patient childbearing age NOT practicing ( Investigator 's opinion ) effective birth control . All female patient must test negative serum pregnancy test study entry negative urine test immediately every certolizumab pegol administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Certolizumab pegol</keyword>
	<keyword>CDP870</keyword>
	<keyword>Cimzia</keyword>
</DOC>